Logo image of INMB

INMUNE BIO INC (INMB) Stock Fundamental Analysis

NASDAQ:INMB - Nasdaq - US45782T1051 - Common Stock - Currency: USD

8.59  -0.5 (-5.5%)

After market: 8.59 0 (0%)

Fundamental Rating

3

INMB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for INMB as it has an excellent financial health rating, but there are worries on the profitability. INMB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INMB has reported negative net income.
In the past year INMB has reported a negative cash flow from operations.
In the past 5 years INMB always reported negative net income.
In the past 5 years INMB always reported negative operating cash flow.
INMB Yearly Net Income VS EBIT VS OCF VS FCFINMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

INMB has a worse Return On Assets (-78.19%) than 68.74% of its industry peers.
Looking at the Return On Equity, with a value of -106.71%, INMB is in line with its industry, outperforming 44.05% of the companies in the same industry.
Industry RankSector Rank
ROA -78.19%
ROE -106.71%
ROIC N/A
ROA(3y)-38.79%
ROA(5y)-35.5%
ROE(3y)-53.97%
ROE(5y)-45.14%
ROIC(3y)N/A
ROIC(5y)N/A
INMB Yearly ROA, ROE, ROICINMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400

1.3 Margins

INMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INMB Yearly Profit, Operating, Gross MarginsINMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K -100K

More info and screens

7

2. Health

2.1 Basic Checks

INMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
INMB has about the same amout of shares outstanding than it did 1 year ago.
INMB has more shares outstanding than it did 5 years ago.
INMB has a better debt/assets ratio than last year.
INMB Yearly Shares OutstandingINMB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
INMB Yearly Total Debt VS Total AssetsINMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 1.92 indicates that INMB is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 1.92, INMB is doing good in the industry, outperforming 70.52% of the companies in the same industry.
There is no outstanding debt for INMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.92
ROIC/WACCN/A
WACC9.58%
INMB Yearly LT Debt VS Equity VS FCFINMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 2.59 indicates that INMB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.59, INMB is doing worse than 71.05% of the companies in the same industry.
INMB has a Quick Ratio of 2.59. This indicates that INMB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.59, INMB is doing worse than 69.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.59
INMB Yearly Current Assets VS Current LiabilitesINMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

INMB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.42%.
INMB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -81.74%.
INMB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 149.33% yearly.
EPS 1Y (TTM)-43.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-81.74%
Revenue growth 3Y149.33%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, INMB will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.75% on average per year.
INMB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 259.90% yearly.
EPS Next Y-40.17%
EPS Next 2Y-9.51%
EPS Next 3Y-1.42%
EPS Next 5Y15.75%
Revenue Next Year-92.14%
Revenue Next 2Y-41.42%
Revenue Next 3Y265.84%
Revenue Next 5Y259.9%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INMB Yearly Revenue VS EstimatesINMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
INMB Yearly EPS VS EstimatesINMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INMB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INMB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INMB Price Earnings VS Forward Price EarningsINMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INMB Per share dataINMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.51%
EPS Next 3Y-1.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INMB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMUNE BIO INC

NASDAQ:INMB (2/21/2025, 8:00:01 PM)

After market: 8.59 0 (0%)

8.59

-0.5 (-5.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners27.99%
Inst Owner Change23.26%
Ins Owners20.37%
Ins Owner Change0.51%
Market Cap190.44M
Analysts85
Price Target22.61 (163.21%)
Short Float %35.01%
Short Ratio13.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.88%
Min EPS beat(2)-18.44%
Max EPS beat(2)22.19%
EPS beat(4)1
Avg EPS beat(4)-3.19%
Min EPS beat(4)-18.44%
Max EPS beat(4)22.19%
EPS beat(8)3
Avg EPS beat(8)-206.28%
EPS beat(12)7
Avg EPS beat(12)-129.8%
EPS beat(16)8
Avg EPS beat(16)-102.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.77%
PT rev (3m)11.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4534.29
P/FCF N/A
P/OCF N/A
P/B 4.92
P/tB 8.59
EV/EBITDA N/A
EPS(TTM)-2.18
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS1.74
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.19%
ROE -106.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.79%
ROA(5y)-35.5%
ROE(3y)-53.97%
ROE(5y)-45.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.59
Quick Ratio 2.59
Altman-Z 1.92
F-Score2
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-40.17%
EPS Next 2Y-9.51%
EPS Next 3Y-1.42%
EPS Next 5Y15.75%
Revenue 1Y (TTM)-81.74%
Revenue growth 3Y149.33%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-92.14%
Revenue Next 2Y-41.42%
Revenue Next 3Y265.84%
Revenue Next 5Y259.9%
EBIT growth 1Y-53.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.82%
OCF growth 3YN/A
OCF growth 5YN/A